Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Verena L. Muzio‐González, Klaudia Urrutia-Pérez et al.|EClinicalMedicine|2022Cited by 69
Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assaysGilda Lemos, Gerardo Guillén, Sheila Chávez-Valdés et al.|medRxiv|2021Cited by 8
Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)Francisco Hernández‐Bernal, Verena L. Muzio‐González, Maria del Carmen Ricardo-Cobas et al.|SSRN Electronic Journal|2022Cited by 5
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Maria C. Ricardo-Cobas, Yenima Martín‐Bauta et al.|medRxiv|2021Cited by 3